Combining chemotherapy and targeted therapies in metastatic colorectal cancer.

Colorectal cancer remains one of the major causes of cancer death worldwide. During the past years, the development of new effective treatment options has led to a considerable improvement in the outcome of this disease. The advent of agents such as capecitabine, irinotecan, oxaliplatin, erbitux and bevacizumab has translated into median survival times in the range of 2 years. Intense efforts have focused on identifying novel agents targeting specific growth factor receptors, critical signal transduction pathways or mediators of angiogenesis. In addition, several clinical trials have suggested that some of these molecularly targeted drugs can be safely and effectively used in combination with conventional chemotherapy. In this article we review various treatment options combining cytotoxic and targeted therapies currently available for patients with metastatic colorectal cancer.

[1]  D. Sargent,et al.  3021 POSTER Association between exposure to bevacizumab (BV) beyond first progression (BBP) and overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): results from a large observational study (BRiTE) , 2007 .

[2]  C. Fuchs,et al.  Updated results of BICC-C study comparing first-line irinotecan/fluoropymidine combinations with or without celecoxib in mCRC: Updated efficacy data , 2007 .

[3]  H. Lenz,et al.  EGFR, Cox-2, and EGF polymorphisms associated with progression-free survival of EGFR-expressing metastatic colorectal cancer patients treated with single-agent cetuximab (IMCL-0144) , 2007 .

[4]  D. Cunningham,et al.  Preliminary efficacy of bevacizumab with first-line FOLFOX, XELOX, FOLFIRI and monotherapy for mCRC: First BEATrial , 2007 .

[5]  P. Gibbs,et al.  Vandetanib with mFOLFOX6 in advanced colorectal adenocarcinoma: An open-label, multicenter phase I study , 2007 .

[6]  H. Lenz,et al.  Polymorphisms in angiogenesis related genes predict clinical outcome in patients (pts) with metastatic colorectal cancer (mCRC) treated with first line 5-FU or capecitabine in combination with oxaliplatin and bevacizumab (FOLFOX/BV or XELOX/BV) , 2007 .

[7]  F. Ciardiello,et al.  Phase I/II study of cetuximab dose-escalation in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST): Pharmacokinetic (PK), Pharmacodynamic (PD) and efficacy data , 2007 .

[8]  W. Scheithauer,et al.  Bevacizumab (Bev) in combination with XELOX or FOLFOX4: Updated efficacy results from XELOX-1/ NO16966, a randomized phase III trial in first-line metastatic colorectal cancer , 2007 .

[9]  P. Jänne,et al.  EGFR, HER2 and Kras as predictive factors for cetuximab sensitivity in colorectal cancer , 2007 .

[10]  A. Jimeno,et al.  Analysis of potential predictive factors of clinical benefit in patients (pts) with metastatic colorectal cancer (MCRC) treated with single-agent cetuximab as first-line treatment , 2007 .

[11]  T. Frebourg,et al.  KRAS mutation is highly predictive of cetuximab resistance in metastatic colorectal cancer , 2007 .

[12]  A. Grothey,et al.  Association between exposure to bevacizumab (BV) beyond first progression (BBP) and overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): Results from a large observational study (BRiTE) , 2007 .

[13]  L. Crinò,et al.  Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  P. Catalano,et al.  Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  L. Grochow,et al.  Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  M. Fakih,et al.  A phase I study of vorinostat (suberoylanilide hydroxamic acid, SAHA) in combination with 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) in patients with advanced colorectal cancer (CRC). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  G. Colucci,et al.  FOLFOX-4 + cetuximab in untreated patients with advanced colorectal cancer. A phase II study of the Gruppo Oncologico dell'Italia Meridionale (prot. GOIM 2402). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  M. Mottolese,et al.  Epidermal growth factor gene amplification is not frequent and cannot account for antitumor activity of cetuximab plus chemotherapy in advanced colorectal cancer patients. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  D. Kerr,et al.  A meta-analysis of two randomized, double-blind, placebo-controlled, phase III studies in patients (pts) with metastatic colorectal cancer (mCRC) receiving FOLFOX4 and PTK/ZK to determine clinical benefit on progression-free survival (PFS) in high LDH pts. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  F. Kabbinavar,et al.  Bevacizumab improves outcomes of patients with metastatic colorectal cancer (mCRC) treated with IFL with or without bevacizumab (BV) independent of baseline risk. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  A. Shields,et al.  Phase I evaluation of AZD2171, a highly potent and selective inhibitor of VEGFR signaling, in combination with selected chemotherapy regimens in patients with advanced solid tumors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  M. Aapro,et al.  MABEL-A large multinational study of cetuximab plus irinotecan in irinotecan resistant metastatic colorectal cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  F. Sekiguchi,et al.  Antitumor activity of erlotinib in combination with capecitabine in human tumor xenograft models , 2006, Cancer Chemotherapy and Pharmacology.

[24]  R. Schwartz,et al.  HER2 expression as a potential marker for response to therapy targeted to the EGFR , 2006, British Journal of Cancer.

[25]  G. Pond,et al.  Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer , 2006, British Journal of Cancer.

[26]  B. Vincenzi,et al.  Lack of response of cetuximab plus oxaliplatin in advanced colorectal cancer patients resistant to both oxaliplatin and cetuximab plus irinotecan. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[27]  T. Seufferlein,et al.  Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[28]  B. Vincenzi,et al.  Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: a single centre phase II trial , 2006, British Journal of Cancer.

[29]  A. Tolcher,et al.  A phase I, pharmacokinetic and biologic correlative study of oblimersen sodium (Genasense, G3139) and irinotecan in patients with metastatic colorectal cancer. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[30]  A. Jubb,et al.  Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  R. Advani,et al.  Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  H. Mackay,et al.  A Phase II Trial with Pharmacodynamic Endpoints of the Proteasome Inhibitor Bortezomib in Patients with Metastatic Colorectal Cancer , 2005, Clinical Cancer Research.

[33]  R. Goldberg,et al.  Systemic therapy for metastatic colorectal cancer: current options, current evidence. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  A. Jubb,et al.  Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. , 2005, Journal of the National Cancer Institute.

[35]  S. Kubicka,et al.  Phase I study of gefitinib in combination with FOLFIRI as 2nd-/3rd-line treatment in patients with metastatic colorectal cancer , 2005 .

[36]  A. Jimeno,et al.  Phase I/II trial of capecitabine and gefitinib in patients with advanced colorectal cancer after failure of first-line therapy , 2005 .

[37]  S. Dakhil,et al.  Cetuximab + FOLFOX 6 as first line therapy for metastatic colorectal cancer , 2005 .

[38]  S. Groshen,et al.  Molecular determinants of cetuximab efficacy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  J. Berlin,et al.  A phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancer , 2005, British Journal of Cancer.

[40]  Silvia Benvenuti,et al.  Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. , 2005, The Lancet. Oncology.

[41]  M. Gonen,et al.  Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with Fluorouracil in patients with advanced solid tumors. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  L. Seymour,et al.  A phase II trial of ZD1839 (Iressa™) 750 mg per day, an oral epidermal growth factor receptor-tyrosine kinase inhibitor, in patients with metastatic colorectal cancer , 2005, Investigational New Drugs.

[43]  J. Dancey.  Inhibitors of the mammalian target of rapamycin , 2005, Expert opinion on investigational drugs.

[44]  Xia Han,et al.  Colorectal cancers with microsatellite instability display mRNA expression signatures characteristic of increased immunogenicity , 2004, Molecular Cancer.

[45]  Jeffrey W. Clark,et al.  Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  E. Van Cutsem,et al.  Phase 1/2a study of EKB-569, an irreversible inhibitor of epidermal growth factor receptor, in combination with 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX-4) in patients with advanced colorectal cancer (CRC). , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  U. Vanhoefer,et al.  Phase I/II study of PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor in combination with FOLFIRI as first-line treatment for patients with metastatic colorectal cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  B. LaFleur,et al.  Changes in epidermal growth factor receptor signaling in serum and tumor biopsies obtained from patients with progressive metastatic colorectal cancer (MCRC) treated with gefitinib (ZD1839): an Eastern Cooperative Oncology Group study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  H. Lenz,et al.  Association of Cyclin D1 (CCND1) gene A870G polymorphism and clinical outcome of EGFR-positive metastatic colorectal cancer patients treated with epidermal growth factor receptor (EGFR) inhibitor cetuximab (C225) , 2004 .

[50]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[51]  L. Greenberger,et al.  Phosphorylation of extracellular signal-regulated kinase 1 and 2, protein kinase B, and signal transducer and activator of transcription 3 are differently inhibited by an epidermal growth factor receptor inhibitor, EKB-569, in tumor cells and normal human keratinocytes. , 2004, Molecular cancer therapeutics.

[52]  N. Magné,et al.  ZD1839 (Iressa) modifies the activity of key enzymes linked to fluoropyrimidine activity: rational basis for a new combination therapy with capecitabine. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[53]  G. Gasparini,et al.  Inhibitors of cyclo-oxygenase 2: a new class of anticancer agents? , 2003, The Lancet. Oncology.

[54]  R. Nicholson,et al.  EGFR and cancer prognosis. , 2001, European journal of cancer.

[55]  N. Goldstein,et al.  Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma , 2001, Cancer.

[56]  G. Fontanini,et al.  Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[57]  C. Punt,et al.  Pharmacokinetics of escalating doses of CCI-779 in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors , 2001 .

[58]  J. Mestan,et al.  PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. , 2000, Cancer research.

[59]  J. Mendelsohn.  Blockade of receptors for growth factors: an anticancer therapy--the fourth annual Joseph H Burchenal American Association of Cancer Research Clinical Research Award Lecture. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[60]  L. Pustilnik,et al.  Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. , 1999, The Journal of pharmacology and experimental therapeutics.

[61]  K. Struhl.  Histone acetylation and transcriptional regulatory mechanisms. , 1998, Genes & development.

[62]  W. Scheithauer,et al.  Cetuximab plus irinotecan for metastatic colorectal cancer (mCRC): Safety analysis of 800 patients in a randomized phase III trial (EPIC). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  Z. Hua.  Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer , 2006 .

[64]  U. Vanhoefer,et al.  Expanded phase I/II study of PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in combination with FOLFOX-4 as first-line treatment for patients with metastatic colorectal cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[65]  D. Cunningham,et al.  Phase I study of gefitinib in combination with irinotecan in patients with fluoropyrimidine refractory advanced colorectal cancer (CRC). , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  G. Gasparini,et al.  Anti-angiogenic therapy: Rationale, challenges and clinical studies , 2004, Angiogenesis.

[67]  F. di Costanzo,et al.  A feasibility study of gefitinib in association with capecitabine (CAP) and oxaliplatin (OXA) as first-line treatment in patients with advanced colorectal cancer (ACRC). , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[68]  F. Kabbinavar,et al.  Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  Martin R. Schneider,et al.  PTK 787 / ZK 222584 , a Novel and Potent Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases , Impairs Vascular Endothelial Growth Factor-induced Responses and Tumor Growth after Oral Administration , 2000 .

[70]  G. Tortora,et al.  Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an EGFR-selective tyrosine kinase inhibitor. , 2000 .

[71]  A. Ullrich,et al.  SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. , 1999, Cancer research.